Amgen's (AMGN) recent developments headlined the biotech industry news. Despite the market fluctuations, the company's shares have seen an overall positive trend. An
FDA approval was granted for Amgen's
Blincyto and
Tarlatamab treatments signifying a well-received endorsement for the company's research efforts. The company's third-quarter earnings and revenue estimates were surpassed, however, concerns over released clinical data resulted in a minor stock dip. Amgen's value rank remained solid at 6, indicating its profitability for value investors. The recent dip in the stock is viewed as a temporary phase by experts, considering its long-term investment value. Also, there's a positive buzz about
Amgen's experimental obesity drug. It outperformed the stock market, marking significant advances in its research. However, analysts anticipate a decline in earnings in the future. Also, the company reported positive Phase 3 results for
UPLIZNA. Amgen has also applied for marketing authorization for
Teprotumumab with the European authorities, demonstrating a strong future outlook.
Amgen AMGN News Analytics from Thu, 09 Nov 2023 06:15:22 GMT to Sun, 23 Jun 2024 19:22:56 GMT -
Rating 8
- Innovation 7
- Information 6
- Rumor -1
